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T antigen is able to transactivate gene expression from the simian virus 40 (SV40) late promoter and from
several other viral and cellular promoters. Neither the mechanisms of transactivation by T antigen nor the
regions of T antigen required for this activity have been determined. To address the latter point, we have
measured the ability of a set of SV40 large T antigen mutants to stimulate gene expression in CV-1 monkey
kidney cells from the SV40 late promoter and Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter.
Transactivation, although reduced, was retained by an N-terminal 138-amino-acid fragment of T antigen.
Mutants with alterations at various locations within the N-terminal 85 amino acids transactivated the RSV LTR
promoter less well than did wild-type T antigen. Most of these were also partially defective in their ability to
transactivate the SV40 late promoter. Two mutants with lesions in the DNA-binding domain that were unable
to bind to SV40 DNA were completely defective for transactivation of both promoters, while a third mutant
with a lesion in the DNA-binding domain which retained origin-binding activity transactivated both promoters
as well as did wild-type T antigen. Only a low level of transactivation was seen with mutant T antigens which
had lesions in or near the zinc finger region (amino acids 300 to 350). Mutations which caused defects in ATPase
activity, host range/helper function, binding to p53, binding to the retinoblastoma susceptibility protein, or
nuclear localization had little or no effect on transactivation. These results suggest that the N-terminal portion
of T antigen possesses an activation activity. The data are consistent with the idea that the overall conformation
of T antigen is important for transactivation and that mutations in other regions that reduce or eliminate
transactivation do so by altering the conformation or orientation of the N-terminal region so that its ability to
interact with various targets is diminished or abolished.

factors and direct interaction between cellular factors and
the ElA protein (44, 52). The herpes simplex virus type 1
VP16 protein is contained within the herpesvirus virion.
Once inside newly infected cells, VP16 acts to stimulate
transcription from a set of herpesvirus immediate-early
genes. The available data indicate that VP16 stimulates
transcription through interactions with protein factors at the
promoter (5, 75, 76, 84). VP16 contains an acidic activating
domain and has proven to be an exceptionally strong trans
activator (67).
Less is known about trans activation by SV40 large T
antigen. Many studies have focused on defining sequence
elements within the SV40 late promoter that are involved in
mediating transactivation by T antigen (10, 38). Other studies have demonstrated that the presence of T antigen causes
alterations in the pattern of cellular transcription factors able
to recognize these key sequences, but the mechanism by
which these changes are caused is not known (4, 20, 21).
Like the adenovirus ElA protein, SV40 large T antigen
has been shown to interact with cellular transcription factors. Mitchell et al. showed that T antigen can form a
complex with transcription factor AP-2 and inactivate it (54).
The importance of this to transcriptional activation by T
antigen is not known. The SV40 regulatory region contains
multiple binding sites for transcription factor Spl. Spl
mRNA and protein levels are increased 100-fold after infection by SV40 (68), suggesting that some of the genes expressed at higher levels after SV40 infection may be induced
indirectly as a consequence of higher levels of SP1 or other
transcription factors in SV40-infected cells.
Since only limited work has been done to define the
portions of T antigen important for transactivation, we set
out to map this activity. T antigen has been subjected to

The large T antigen of simian virus 40 (SV40) is a multifunctional 708-amino-acid phosphoprotein that plays diverse
roles during the SV40 infection cycle (for review, see reference 69). Enzymatically, T antigen is able to bind and
hydrolyze ATP. Additionally, it binds specifically to pentanucleotide sequences within the SV40 origin of replication
and possesses nonspecific DNA-binding activity. Through
coordination of these activities, T antigen plays a central role
in the initiation of viral DNA replication, by catalyzing the
unwinding of viral DNA at the origin, and in elongation, by
acting as a helicase at the replication fork (for review, see
reference 60). It may also have additional roles in viral DNA
replication.
A second major arena of T antigen activity is transcription. T antigen autoregulates the level of SV40 early mRNA
through direct binding to sequences on the early side of the
origin of replication (2, 30, 40, 62, 65). In addition, T antigen
activates transcription from the SV40 late promoter (8, 10,
37) and is also able to transactivate transcription from a
variety of other viral and cellular promoters (1, 9, 48, 68, 73).
This activity may be responsible for the observed induction
of increased levels of enzymes involved in DNA replication
(for reviews, see references 78 and 79).
The mechanisms by which some viral transactivators such
as adenovirus ElA and herpes simplex virus type 1 VP16
stimulate transcription has been studied extensively. The
adenovirus ElA protein acts to stimulate transcription from
the E1B, E2, E3, E4, and major late promoters and appears
to affect these through multiple mechanisms (43, 63, 85),
including modification or induction of cellular transcription
*
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extensive genetic analysis, permitting the assignment of
many of its activities to distinct regions of the polypeptide.
The DNA-binding domain is known to require sequences
between amino acids 131 and 259 (3), but DNA-binding
activity is affected by the presence of additional sequences,
including a zinc finger region near amino acid 300 (34). Much
of the C-terminal half of the polypeptide (residues 400 to 600,
approximately [11, 12, 14, 55]) constitutes an ATP-binding
and ATPase domain that has homology to domains found in
many other proteins that also bind and hydrolyze ATP (7).
The C terminus of T antigen is not required for the replicative activities of T but provides a host range function;
mutants lacking the C terminus produce drastically reduced
virus yields in some monkey kidney cell lines (39, 74, 80-82).
Regions of T important for nuclear localization (amino acids
[aa] 126 to 132 [35, 36, 42]) and for binding to the tumor
suppressor protein pl05Rb (aa 105 to 115) have also been
mapped precisely (15, 18, 49, 56). T antigen binds a second
tumor-suppressor protein, p53, but the minimal sequences
required for this interaction have not been determined (55,
71). The amino-terminal 130 amino acids of large T are
required for transformation of virtually all rodent cell lines
examined (73); this portion alone is sufficient to transform
C3H 1OT1/2 cells, while transformation of most other cell
lines requires substantially more T antigen, including most of
the first 600 amino acids (59, 77).
In the experiments described below, we measured the
ability of a large set of SV40 mutants to stimulate gene
expression from the SV40 late and Rous sarcoma virus
(RSV) long terminal repeat (LTR) promoters. Mutants with
alterations at various locations within the N-terminal 85
amino acids transactivated the RSV LTR promoter less well
than did wild-type T antigen. Most of these were also
partially defective in their ability to transactivate the SV40
late promoter. Mutants with lesions in the DNA-binding
domain that were unable to bind to SV40 DNA were
completely defective for transactivation of both promoters.
Another mutant with a lesion that mapped within the DNAbinding domain but which retained the ability to bind to the
SV40 origin transactivated as well as wild-type T antigen
did. Only a low level of transactivation was seen with mutant
T antigens with lesions in or near the zinc finger region (aa
300 to 350). Mutations in the C-terminal half of T antigen had
little effect on transactivation.
We suggest that the N-terminal portion of T antigen possesses an activation activity and that this activity is sensitive
to the physical orientation of this domain with respect to the
overall structure of the protein. In addition, we discuss the
possible relationships between this function of T antigen and
its other activities.

MATERIALS AND METHODS
Plasmids used in this study. Transfection of bacterial
cultures (51), analysis of minilysate preparations of DNA (6),
and large-scale preparation of purified plasmid DNA (13)
were performed by established methods. All plasmids were
propagated in Escherichia coli HB101.
(i) Reporter plasmids. Both pL16n-CAT (38) and pRSVCAT are derivatives of pSVO-CAT (27). pL16n-CAT has a
405-bp HindIII-NcoI fragment from the SV40 origin region
inserted into the HindIII site of pSVO-CAT. In this plasmid,
the SV40 late promoter region is upstream from chloramphenicol acetyltransferase (CAT) coding sequences. pRSVCAT (26) contains a 524-bp fragment, including the RSV
LTR promoter, inserted into the HindIlI site of pSVO-CAT,
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cat mRNA synthesis under control of the RSV
promoter.
In order to facilitate production of large quantities of
plasmid DNA, the pBR322 sequences originally in pSVOCAT and these other derivatives of it were replaced with
pUC18 sequences. To accomplish this, pL16n-CAT and
pRSVLTR-CAT were digested with HindlIl and PstI or PstI
and NdeI, respectively. The appropriate fragments, containing the promoter, cat gene, and RNA processing signals,
were inserted into pUC18. The new plasmids, pUL16n-CAT
and pURSVLTR-CAT, respectively, functioned identically
to the original plasmids in CAT assays (data not shown).
(ii) Plasmids for producing probes for DNA assays. pGEMCAT was constructed from pE2-CAT (47) by cutting pE2CAT with ScaI and PvuII. A 516-bp fragment containing the
CAT coding region was gel purified by using Geneclean (Bio
101, San Diego, Calif.) and inserted into the SmaI site of

bringing

pGEM1.
(iii) Plasmids containing SV40 mutant genomes. Plasmid
pCC2pA contains the entire SV40 genome, opened at its

EcoRI site and inserted into the EcoRI site of pUC18 in an
orientation which places the BamHI site of SV40 close to the
BamHI site in the pUC18 polylinker. Various SV40 mutants
were maintained as recombinant clones inserted into pUC18
in the same orientation as in pCC2pA. p6-1 contains a 6-bp
deletion at the BglI site in the SV40 origin region and
therefore is not able to replicate in the presence of wild-type
SV40 large T antigen (24; data not shown). To produce
replication-defective forms of SV40 variants with mutations
in the second exon of the large T antigen coding sequence,
each mutation was moved into the p6-1 plasmid by replacing
the BstXI-ApaI fragment of p6-1 with an equivalent fragment
containing the mutation. To produce replication-defective
forms of mutants with lesions in the first exon of large T
antigen, a small deletion was created at the Sfi1 site within
the origin of replication of each of these mutants by digesting
plasmids containing SV40 mutant genomes with Sfi1 (which
cuts only at the site within the SV40 origin), removing the 3'
extensions by using the Klenow fragment of DNA polymerase I and deoxynucleoside triphosphates (dNTPs), and recircularizing with T4 DNA ligase. This procedure deleted 3
bp from the center of the origin of replication. The precision
of this mutagenesis was confirmed by determining that the
resulting plasmids no longer contained an Sfil site within the
origin region and that a SacII site had been created at the site
of the deletion. The resulting plasmids were not able to
replicate in the presence of wild-type large T antigen (data
not

shown).

Partial digestion of p6-1 DNA with PJfMI at nucleotide (nt)
4458 of SV40, followed by treatment with the Klenow
fragment of DNA polymerase I and four dNTPs, generated
blunt-ended linear molecules lacking the 3-nt 3' extensions
produced by PflMI digestion. The linear DNA was either
circularized directly with T4 DNA ligase, generating mutant
dl2834, or ligated in the presence of an excess amount of

12-bp nonphosphorylated synthetic oligonucleotide linkers,
d(TCGCGATCGCGA), as described previously (86), generating in2835. dl2834 encodes a large T antigen which contains an Asn residue in place of the Thr and Tyr residues at
positions 85 and 86 of large T antigen. The T antigen encoded
by in2835 also lacks the Thr and Tyr residues at positions 85
and 86 and contains, in their place, Ile-Ala-Ile-Ala-Asn.
(iv) Plasmids containing binding sites for SV40 large T
antigen. Digestion of pCC2pA (wild-type SV40 genome in
pUC18) with HindlIl generated several fragments, including
one of 1,118 bp that contains the complete SV40 origin
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region, including binding sites I, II, and III (65, 72). p1097 is
SV40 mutant with a 31-bp deletion that removes binding
site I (17). Digestion with HindIII generated an 1,100-bp
fragment containing binding sites II and III. pON contains a
19-bp synthetic oligonucleotide version of binding site I (66);
a 626-bp Sall-HindIII fragment of this plasmid was used in
DNA-binding studies.
Transactivation assays. CV-1 monkey kidney cells were
maintained in Dulbecco's modification of minimal essential
medium (GIBCO) supplemented with 10% newborn calf
serum (Hyclone, Logan, Utah) and antibiotics. Transactivation assays were performed by cotransfecting CV-1 cells
with 4.0 ,ug of a plasmid containing wild-type SV40 or an
SV40 mutant genome, 0.5 ,ug of a reporter plasmid, and 15.5
jig of salmon sperm DNA. The reporters used contained the
bacterial CAT coding region downstream from either the
SV40 late promoter of the RSV LTR promoter. We used the
calcium phosphate method to introduce the DNAs into cells
(28). To monitor transfection efficiency, we included in a
parallel plate a control transfection with pSV2APAP DNA
(32), encoding placental alkaline phosphatase. After 45 h,
cells expressing placental alkaline phosphatase were detected histochemically by using naphthol AS-MX phosphate
alkaline solution and fast violet B (both from Sigma Chemical Co., St. Louis, Mo.) as directed by the manufacturer. At
45 h after transfection, we also prepared extracts of transfected cells in the following manner. Cells were washed
twice with TS (25 mM Tris Cl [pH 7.5], 137 mM NaCl, 5 mM
KCl, 0.6 mM Na2HPO4, 0.05 mM MgCl2, 0.7 mM CaCl2),
and 1 ml of TS was added to washed plates. Cells were
scraped off the plate with a cell scraper, centrifuged briefly in
a microfuge, resuspended in RSB (10 mM Tris Cl, 10 mM
NaCl, 1.5 mM MgCl2 [pH 7.35]) containing 0.4% Nonidet
P-40 (NP-40), and incubated at 0°C for 30 min. The nuclei
were pelleted, and the supernatant, containing the CAT
activity, was carefully removed.
To assay the amount of CAT enzyme present in each
sample, we used a modification of the method of Neumann et
al. (58). This assay uses [3H]acetyl coenzyme A (CoA) and
measures direct diffusion of the labeled product (acetylated
chloramphenicol) into water-immiscible liquid scintillation
counting fluid (Econofluor; Du Pont). Only the acetylated
derivatives of chloramphenicol are able to enter this organic
phase. Portions of cell extracts were added to 100 ,ul of CAT
reaction buffer (125 mM Tris Cl [pH 7.8], 2.5 ,uCi of
[3H]acetyl CoA [200 mCi/mmol; Du Pont, Boston, Mass.]
per ml, 1.25 mM chloramphenicol). Since chloramphenicol
was present in large excess compared with the concentration
of [3H]acetyl CoA, the initial rate of acetylation of chloramphenicol was proportional to the concentration of [3H]acetyl
CoA, and the rate constant (K) is a measurement of the
amount of CAT enzyme present in each extract. Since all
CAT reactions were conducted with the same concentration
of [3H]acetyl CoA, the only measurements required were
time elapsed since the acetylation reactions began and
amount of radioactivity detected in the scintillation fluid. In
practice, a set of samples were each counted for 0.1- min
several times during a 4-h period, and these data were
plotted against elapsed time. Background radioactivity was
subtracted, and the rate constants were calculated. This
method was standardized and validated by use of a range of
concentrations of purified CAT enzyme (Sigma). When using
CAT enzyme, the same results were obtained whether or not
an aliquot of a mock-transfected extract was added to the
reaction mixture.
To determine the amount of plasmid DNA present in
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transfected cell cultures, the nuclear pellet was solubilized
by the addition of Hirt's solution (0.1 M Tris Cl, 0.6%
sodium dodecyl sulfate [SDS], 0.1 M EDTA [pH 7.5]) (33),
and the plasmid DNA was separated from chromosomal
DNA by centrifugation at 4°C in an Eppendorf 5413 centrifuge. The supernatant, containing low-molecular-weight episomal DNA, was phenol extracted, depurinated in 0.25 M
HCl for 3 to 5 min, denatured in 0.6 M NaOH-1.5 M NaCl,
neutralized with 1 M Tris C1-1.5 M NaCl, pH 7.0, and
applied to nitrocellulose membranes with a slot blot apparatus (Schleicher & Schuell, Keene, N.H.). The membrane
was baked in vacuo for 1 h at 80°C. The amount of plasmid
DNA in each sample was determined by hybridization of the
membrane to a cat-specific probe made by oligolabeling (19)
a twice-gel-purified 529-bp SacI-BamHI fragment containing
part of the CAT protein coding region. The purity of the
probe was tested by hybridization to known quantities of
either pURSVCAT or p6-1 (origin-defective SV40 cloned
into pUC18). The signal generated with p6-1 was less than
0.5% of the signal generated with an identical amount of
pURSVCAT DNA.
Autoradiograms of the slot blots were quantitated by using
the MasterScan Interpretive Densitometer (Scanalytics, Division of CSP, Inc., Billerica, Mass.).
DNA-binding assays. The DNA-binding activity of mutant
SV40 large T antigens were assayed by using extracts from
mouse cell lines expressing mutant or wild-type T antigens.
Exponentially growing cells were lysed by incubation in
EBC (15) (50 mM Tris Cl [pH 8.0], 100 mM NaCl, 0.5%
NP-40, 0.1 trypsin inhibitor units of aprotinin per ml [Sigma],
added just prior to use) at 4°C for 20 min, and the supernatants were separated from cellular debris by centrifugation in
an Eppendorf 5413 centrifuge at 4°C for 15 min. The amount
of T antigen present in each lysate was estimated by immunoprecipitation with anti-T antibodies (PAb901 and PAb9O2;
gifts from Satvir Tevethia), followed by Western immunoblot analysis. Western blots were probed with anti-T antibodies PAb901 and PAb9O2, followed by '25I-labeled goat
anti-mouse immunoglobulin antibody (Amersham, Arlington
Heights, Ill.). The amount of each cell lysate used was
adjusted so that approximately equal amounts of different
mutant T antigens were analyzed.
The substrate DNA fragments for binding were produced
by digestion of pON with Sall and HindIII, digestion of
p1097 with HindIII, and digestion of pCC2pA with HindIII.
The DNA fragments were radiolabeled by using the Klenow
fragment of DNA polymerase I in the presence of [ot32P]
dCTP (50 ,uCi; specific activity, 3,000 Ci/mmol) and unlabeled dATP, dTTP, and dGTP to fill in the 3' recessed ends.
T antigen-containing (or control) cell lysates were mixed
with 2 ,lI of PAb9O2 ascites fluid and rocked at 4°C for 1 h.
Then 20 ml of protein A-Sepharose beads (Pharmacia; a 1:1
suspension in Tris-buffered saline [25 mM Tris Cl [pH 8.0],
120 mM NaClI] containing 10% bovine serum albumin [BSA;
Sigma]) was added to the T antigen-antibody mixtures and
rocked for 30 min at 4°C. Antibody-T antigen complexes
were collected by centrifugation, and the Sepharose beads
were washed three times with 1 ml of EBC and once with 1
ml of DNA-binding buffer (10 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, pH 7.0], 80 mM KCl,
1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride,
0.2 mg of glycogen per ml, 1 mg of BSA per ml). The
immunocomplexes were then incubated on ice for 1.5 h in a
total volume of 0.5 ml of DNA-binding buffer containing 10
ng of end-labeled pON fragments and 25 ng of end-labeled
pCC2pA or p1097 fragments. The DNA binding reactions
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FIG. 1. Map of SV40 large T antigen and mutations used in this study. The protein backbone of T antigen is indicated by the shaded bar.
The dark grey shading within the bar indicates domains of known function, which are also indicated by labeled brackets below the map. The
exonI-exonlI junction at amino acids 82 and 83 is indicated by a vertical dashed line. Vertical spikes on the map indicate each 100 amino acids.
In-frame deletion mutations are designated by the suffix -(if), and those which cause frameshift mutations are designated by the suffix -(fs).
Mutations which reduce the level of transactivation are indicated above the map, and mutations which do not have a significant effect are
indicated below.

performed in the presence of a 20-fold excess of
sonicated salmon sperm DNA and with an excess of labeled
fragments, relative to the amount of T antigen. The DNAprotein A-Sepharose beads were then washed three times
with phosphate-buffered saline containing 0.4% NP-40 and
resuspended in 30 ,ul of 2x Laemmli's sample buffer (125
mM Tris Cl [pH 6.8], 4% SDS, 20% glycerol, 10% 2-mercaptoethanol [41]). The DNA fragments bound to T antigen
were released by heating at 70°C for 15 min, the Sepharose
beads were removed by centrifugation for 30 s in a microfuge, and the DNA fragments in the supernatants were
analyzed by electrophoresis on 1.5% agarose gels in TBE
buffer (89 mM Tris-OH, 89 mM boric acid, 2.5 mM EDTA
[pH 8.5]). The gels were dried and exposed to X-ray film
(Kodak XAR-5).
were

RESULTS
Transactivation of the RSV LTR and the SV40 late promoter. We examined the ability of a large set of SV40 large
T antigen mutants to activate transcription from the SV40
late and the RSV LTR promoters. The mutants used in these
studies are shown in Fig. 1 and contain mutations located
throughout the T antigen coding region. The 2400 series
mutants were described previously (80, 81) and contain small
deletions. Some encode nearly full-length T antigens lacking
one to four amino acids at the site of the deletion; in others,
the deletion causes a translational reading frame shift, resulting in the production of a T antigen truncated near the
site of the deletion. Most of the mutants in the 2800 series
contain linkers inserted at various sites within the early
region of SV40 (86). A few point mutants were also examined.
Plasmids encoding each of these mutant SV40 T antigens
were cotransfected with a cat reporter plasmid containing
either the SV40 late or RSV LTR promoter sequences into
CV-1 monkey kidney cells. Since wild-type T antigen and

some of the mutant T antigens used in these studies were
competent for viral DNA replication, the SV40 origin of

replication was inactivated in all plasmids. Therefore, none
of the plasmids could be amplified in the transfected cells.
Both cytoplasmic extracts and nuclear DNA were prepared from each transfected culture. CAT enzyme activity
was determined by the method of Neumann et al. (58) and
standardized to the amount of reporter plasmid DNA in the
transfected cells as determined by slot blot analysis.
We first compared three mutants that produce T antigens
truncated after 138 (dlA2420), 510 (dlA2416), or 676
(dlA2459) amino acids. The relative ability of these three
mutants (wild-type T antigen = 1.00) to transactivate the
RSV LTR promoter and the SV40 late promoter is displayed
in Fig. 2. The data indicate that transactivation of the RSV
LTR promoter was not affected significantly by truncation at
amino acid 510 or 676 within the carboxy-terminal half of T
antigen. Transactivation of the SV40 late promoter was
reduced slightly, to 60 to 80% of wild-type levels, by
truncation at these sites. Less activity on either promoter
was seen with the N-terminal 138 amino acids of large T
(dlA2420), which transactivated only 30 to 50% as well as
wild-type SV40 large T.
We extended this study by examining a larger group of
mutants that produce T antigens of approximately full
length. The results from analyses of mutants with lesions in
the C-terminal half of T antigen are shown in Fig. 3. These
mutants have deletions or insertions at amino acids 409
(inA2809), 424 (inA2811), 460 (inA2821), 464 (inA2823), 509
(dlA2432), 520 (inA2827), or 587 (dlA2433). Each of these
transactivated both promoters at 60 to 140% of the level of
wild-type T antigen, confirming the conclusion with the
truncation mutants (Fig. 2) that sequences within the C-terminal half of the molecule are dispensable for transactivation. This region has been shown to contain the ATP-binding
and ATPase domains of T antigen and to play a role in
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is indicated below the mutant number, as are any additional amino acids encoded in the new reading frame, which are indicated after a + sign.
Data are normalized to the level of CAT enzyme produced in the presence of wild-type (wt) T antigen. In the upper graph, the reporter
construct was pRS V-CAT (RSV LTR promoter), and in the lower panel it was pUL16nCAT (SV40 late promoter).

transformation of some rodent cell lines and in immortalization of primary mouse embryo fibroblasts.
Data obtained from analyses of mutants with lesions
affecting the N-terminal half of T antigen are shown in Fig. 4.
Several mutants with lesions within the first 85 amino acids
of large T showed significantly reduced transactivation of the
RSV LTR (Fig. 4). These included mutants with insertions at
amino acids 4 (in2801), 34 (inA2803), and 85 (in2835) as well
as one with a deletion from amino acids 4 to 34 (dIA2831) or
85 (d12834). Some of these showed similar reduced activity
for transactivation of the SV40 late promoter (Fig. 4), while
others (in2801, dlA2831, and inA2803) transactivated the
SV40 late promoter as well as did wild-type T antigen. This
region is absolutely required for transformation of established rodent cell lines (73).
Several mutations in the DNA-binding domain of SV40 T
antigen had a more dramatic effect on transactivation. Two
mutants, dlA2411 (deletion of aa 143 to 146) and inA2815

(insertion at aa 168) failed to transactivate either the SV40
late or RSV LTR promoter (Fig. 5). However, a third
mutation in the DNA-binding domain (inA2817, insertion at
aa 219) transactivated as well as wild-type T antigen did.
Mutants with lesions between amino acid 85 and the

DNA-binding domain (d12441, Ki, and SVcT) also showed
wild-type levels of transactivation (Fig. 5). This region is
important for nuclear localization of T antigen and for
binding to the retinoblastoma protein pl05Rb; mutants examined included ones defective in each of these two properties. Our results indicate that efficient nuclear localization
or binding to pl05Rb is not required for transcriptional
activation of either the SV40 late or RSV LTR promoter.
SV40 large T antigen contains a zinc finger motif, located
between amino acids 300 and 325 (45, 46). This region lies
between the minimal DNA-binding domain (aa 131 to 259)
and the ATPase/ATP-binding domain (aa 400 to 600). The
helicase activity of T antigen requires sequences extending
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FIG. 3. Transactivation by SV40 large T antigen mutants which produce nearly full-sized T antigens with lesions in the C-terminal half of
T antigen. The means of the data from Fig. 2 are indicated to the left of the vertical dotted line in darker shading. For Fig. 3 through 6, the
identity of each plasmid is indicated below each set of data, as is the nature of the mutation it carries and the location of the amino acids of
T antigen that are affected. The prefix in- represents an insertion of a 12-bp linker; the suffix +in represents a linker inserted at the site of the
deletion; the prefix dl- represents a deletion of the indicated amino acids; point mutants are indicated by the wild-type single-letter amino acid
code, followed by its location and the mutant amino acid which replaces it.

from the DNA-binding domain through the ATPase domain.
Coordination between these regions is probably essential for
this activity and is a likely function of the zinc finger motif.
The transformation function of large T is substantially reduced by mutation of this motif (45, 46). Two mutants
containing mutations in this region, one within (inA2807, aa
303) and one adjacent to (inA2819, aa 346) this motif,
transactivated both promoters approximately 30% as well as
wild-type T (Fig. 6). These mutants transactivated to a
greater extent than negative controls, but their activity was
always low.
In summary, sequences within the N-terminal half of T
antigen appear to play an important role in transactivation.
Transactivation was reduced but not eliminated by mutations within the first exon or within or near the zinc finger
region. Transactivation, although reduced, was retained by
an N-terminal 138-amino-acid fragment of T antigen, while
some mutants with lesions in the DNA-binding domain were
completely defective for transactivation of both promoters
examined.

Determination of the DNA-binding activity of mutants of
SV40 large T antigen. The origin-binding activity of T antigen
cannot be absolutely required for transcriptional activation,
since a 138-amino-acid N-terminal fragment of T antigen
retained substantial activity (Fig. 2). However, since two
mutants (dlA2411 and inA2815) with lesions in the DNAbinding domain were completely defective for transactivation while one (inA2817) showed a wild-type level of transactivation (Fig. 5), we wondered whether DNA binding was
important for transactivation by mutant T antigens of approximately wild-type size. Therefore, we measured the
ability of mutant T antigens to bind to the SV40 origin region.
We performed McKay-type DNA-binding assays (53). To
provide adequate quantities of wild-type and mutant T
antigens, we prepared extracts of exponentially growing
mouse cells expressing various T antigens. The concentration of wild-type and mutant T antigens in these extracts was
determined by Western blotting (data not shown) so that
approximately equal amounts of each T antigen could be
used in DNA-binding experiments.
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Wild-type SV40 DNA contains three large T antigenbinding sites. Site I contains three 5'-GAGGC-3' pentanucleotides. Site II, which contains four pentanucleotides with
two oriented in each direction, is contained within the
minimal origin and is essential for SV40 DNA replication.
The binding of T antigen to both sites I and II is responsible
for repression of the early promoter by T antigen (65). Site
III is located on the late promoter side of site II; T antigen
binds to site III at a very low affinity, and it was not possible
to detect site III binding in this assay. The fragments used
for this assay are shown in Fig. 7A. A 1,118-bp HindlIl
fragment of wild-type SV40 DNA contains all three T
antigen-binding sites. p1097 contains a deletion which removes binding site I; the binding of the 1,100-bp fragment to
T antigen represents site II binding, since T binds to site III
very weakly. The third substrate for binding was a 626-bp
Sall-HindIll fragment from pON, which contains a synthetic
oligonucleotide form of site I inserted into plasmid pAT153.
32P-3'-end-labeled DNA fragments were incubated with immunocomplexes formed between T antigen and monoclonal
antibodies PAb9O1 and PAb9O2. After incubation, unbound
DNA fragments were washed away. The DNA fragments

bound to T antigen were then released and analyzed by
agarose gel electrophoresis (Fig. 7B).
Wild-type T antigen binds to site II much more weakly
than it does to site I or to the complete wild-type origin
(reviewed in reference 16). Mutants inA2827 and dIA2433
have lesions that are outside of the DNA-binding domain of
T antigen. They transactivated both the SV40 late and RSV
LTR promoters at wild-type efficiency and bound to sites I
and II as well as or better than wild-type T antigen. The T
antigen encoded by dIA2433 is unstable (80). The fact that an
equal amount of this T antigen bound more radiolabeled
DNA than did wild-type T may reflect the fact that there
would likely be more newly synthesized mutant T antigen in
the extract. Newly synthesized T antigen is more active for
DNA binding (70).
Three mutations which map within the minimum originbinding domain defined by Arthur et al. (3) were used in this
study. Two of these mutants, dlA2411 and inA2815, did not
transactivate either promoter examined, and both failed to
bind either site I or II (Fig. 7B). The other mutant, inA2817,
transactivated the two promoters as efficiently as the wild
type and bound both site I and site II at the wild-type level.
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Mutant inA2807 has a 12-bp insertion within the zinc finger
motif (aa 302). This mutant T antigen was unstable (86),
failed to bind DNA, and showed a reduced ability to transactivate the promoters studied. Two mutants with lesions in
the first exon (in2801 and inA2803) bound to sites I and II as
well as wild-type T did. These results indicated that, for T
antigens of nearly full size, the ability to bind to the SV40
origin region or the conformation of the protein required for
this binding is important for transactivation.

DISCUSSION
The experiments described in this article were conducted
in order to map the transactivation domain of SV40 large T
antigen and, by so doing, to provide information essential for
determining whether transactivation is related to any of the
other activities or properties of large T antigen.
In each experiment, several mutants were compared and a
common set of controls were performed, including transactivation by wild-type T antigen, transactivation by a plasmid
which encoded no T antigen (e.g., pUC18), and analysis of
the level of reporter expression in cells which received only
the reporter plasmid and carrier DNA. We noticed that CAT
expression could be stimulated two- to fourfold by various
plasmids which did not encode any transactivator. These

included pUC18, pBluescriptKS+, and pBR322. We do not
understand the mechanism of these plasmid effects, but they
could reflect the titration of a negative factor by the plasmid,
permitting a higher basal level of reporter gene transcription
in the absence of transactivator. Since'some of the T antigen
mutants studied stimulated cat expression only slightly (but
reproducibly) more than pUC18, caution is required in
interpreting these data.
For mutants that transactivated at close to wild-type
levels, it is safe to conclude that the mutated region of T
antigen was not required for transactivation. When mutants
showed levels of transactivation consistently greater than
that seen with pUC18 but only 30 to 80% of that of wild-type
T, the mutation clearly affected the ability of wild-type T to
transactivate. A few mutants examined consistently transactivated to a level only slightly greater than that seen with
pUC18. With these (dlA2420, inA2807, and inA2819), we
believe that the mutant T antigens retained some transactivation activity but that plasmid-based effects may be responsible for part of the stimulation observed. For the mutants
which completely failed to transactivate (dlA2411 and
inA2815), the mutant T antigens likely had no activity at all
but may also have been able to prevent the low level of
stimulation resulting from plasmid effects.
What portions of SV40 large T antigen are involved in
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transactivation? The results obtained suggest that the first 85
amino acids are important for transactivation. All mutants
examined with lesions in this region showed a reduced
ability to transactivate the RSV LTR promoter and some
were also reduced in transactivation of the SV40 late promoter. The importance of this region also follows from the
finding that a 138-amino-acid N-terminal fragment of T
antigen (dlA2420) retained the ability to transactivate both
promoters, albeit at a low level. Srinivasan et al. reported
previously that the N-terminal 121 amino acids of T antigen
transactivated the adenovirus E2 promoter (73).

The fact that all of the mutations in this region reduced but
did not completely eliminate transactivation of the RSV LTR
promoter is reminiscent of observations of mutants within
the transactivating regions of Gal4 of Saccharomyces cerevisiae (22, 50) and the herpes simplex virus type 1 transactivator, VP16 (67, 83). In both of these, maximal activity was
seen when the entire transactivating region was present, but
mutants lacking portions of this region retained partial
activity. Both Gal4 and VP16 contain acidic transactivating
domains, and the overall acidity seems to be more important
than the particular sequence of acidic residues.
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cloned into the EcoRI site of pUC18, includes both site I and site II; pON, an artificial site I cloned into pAT153, includes only site
I; p1097, an SV40 genome with a 31-bp deletion at the site I cloned into pAT153, contains only site II. Thin lines represent SV40 DNA
sequences, and arrows represent the pentanucleotide (5'-GAGGC-3') consensus sequence. The sizes of the restriction fragments containing
the corresponding T antigen-binding site are indicated to the right of each map. (B) Cells expressing mutant T antigens were lysed, and mutant
T antigens were immunoprecipitated with PAb902 (two left panels) or PAb901 (two right panels). The immunocomplexes were then incubated
with an equal molar amount of 32P-labeled SalI- and HindIII-digested pON and HindIII-digested pCC2pA (two upper panels) or
HindIll-digested p1097 and pON (two lower panels). The DNA fragments bound were released in phosphate-buffered saline containing 0.4%
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In contrast to the acidic activating domains of VP16 and
Gal4, the N-terminal 85-amino-acid portion of large T has a
nearly neutral overall charge but is highly hydrophilic (14
acidic and 15 basic residues, two serines and three threonines) and is likely to be located at the surface of T antigen,
where it could interact with other macromolecules. Possibly,
the inability to find single mutations within this region that
eliminate all transactivation activity could indicate that a
large surface of T antigen interacts with other protein
factors.
The ability of T antigen to transactivate was also affected
by mutations in a second region of T antigen, the DNAbinding domain. Of the three mutants examined, the two
which failed to bind to the SV40 origin region (dlA2411 and
inA2815) were completely defective for transactivation,
while one which retained binding activity (inA2817) transactivated as well as the wild type did. Keller and Alwine
showed previously (37) that mutant C6 (23), which is defective in DNA binding (61), did not transactivate the SV40 late
promoter. These observations raise two important questions. Is the DNA-binding activity of large T important for its
role in transactivation? Is there more than one domain of T
antigen with transactivation activity, or does a single transactivation domain include sequences that extend into or
beyond the DNA-binding domain?
T antigen transactivates a variety of viral and cellular
promoters (1). Among them, only the SV40 late promoter
constructs contained sites for specific binding of T antigen.
Therefore, if binding to DNA were important for transactivation, this would have to be mediated through T antigen's
nonspecific DNA-binding activity. Furthermore, two mutant
proteins which retained a reduced level of transactivation,
the 138-amino acid N-terminal fragment of dlA2420 and the
full-length protein of inA2807, were defective for DNA
binding. The truncated protein produced by dlA2420 lacks
the DNA-binding domain, while the full-length protein produced by inA2807 failed to bind to DNA specifically. This
suggests that site-specific DNA binding cannot be absolutely
required for transactivation by T antigen.
T antigen could contain two distinct transactivation domains-the first with the N-terminal 138 amino acids and the
second within the DNA-binding domain. Full transactivation
could require the presence of both. Our data indicate that a
low level of transactivation occurred when only the first 138
amino acids were present. However, no transactivation was
seen with some mutants with lesions in the DNA-binding
domain, even though the normal N-terminal 142 (dlA2411) or
167 (inA2815) amino acids were present. This argues against
the existence of two independent transactivation domains.
Whether transactivation activity would be displayed by the
DNA-binding domain alone or by mutant proteins which
were initiated downstream from the normal initiation site
will require analysis of additional mutants.
If a transactivation domain were located at the amino
terminus, activity of this domain might require a particular
conformation or orientation with respect to the remainder of
T antigen. Mutants with lesions in the DNA-binding domain
which retained DNA-binding activity probably possess an
overall conformation similar to that of wild-type T antigen.
Mutants such as inA2815 which have lost the ability to bind
to SV40 DNA and to transactivate the SV40 late and RSV
LTR promoters could be defective for both binding and
transactivation because of either altered conformation or the
specific loss of DNA-binding activity. Distinguishing between these possibilities will also require analysis of additional mutant T antigens.
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An additional possibility consistent with the data presented above is that the domain most important for transactivation maps to sequences extending from upstream of
amino acid 85 into or through the DNA-binding domain. All
mutants with lesions in the first exon retained some ability to
transactivate, and these mutations could have altered the
overall conformation of the proteins, thereby reducing but
not eliminating their ability to transactivate. By this model,
amino-terminal fragments of T antigen would be able to
transactivate at a reduced level, since they would retain part
of a transactivating domain. Since the first 167 residues of
inA2815 T antigen are wild type and this mutant totally failed
to transactivate, this model would also require that this and
other mutant T antigens which completely failed to transactivate fold so as to prevent any activating domain from
interacting with its target.
Another region where mutations substantially decreased
the transactivation activity of T antigen was the zinc finger
motif and sequences adjacent to it. Mutants with mutations
within (aa 302, inA2807) or nearby (aa 346, inA2819) showed
a reproducible low level of activity. This region is thought to
be important for the overall conformation of T antigen and to
coordinate the interactions between DNA binding and the
ATP-binding/ATPase domains. Mutations in this region
could affect the orientation and environment of a specific
activation domain and decrease its ability to interact with the
targets required for activation of gene expression.
Several mutants which transactivated the RSV LTR less
well than did wild-type T transactivated the SV40 late
promoter at wild-type levels. This probably reflects the fact
that these two transcriptional control regions are quite
different (21, 25, 29). Different transcription factors are
involved in transcription from these two promoters, and
therefore the role played by T antigen in transactivation of
each may be different. Consequently, mutant T antigens
which show partial transactivation of one promoter may
fully transactivate the other if different T antigen-transcription factor interactions are involved.
How does T antigen transactivate? The mechanism by
which T antigen transactivates is not understood. We can
imagine various possibilities. T antigen could interact directly with transcription factors at the promoter. Currently,
there is little evidence for this. Although addition of T
antigen to in vitro transcription systems increases the rate of
transcription initiation, these increases are smaller than
those seen in vivo (31, 57, 64). Alternatively, T could act
indirectly. For example, T could act to increase the activity
or abundance of one or more transcription factors. Gallo et
al. have shown that there are quantitative and qualitative
changes in proteins able to bind to critical sequences within
the SV40 late promoter in monkey kidney cells expressing T
antigen (21). SV40-infected cells contain 100-fold higher
levels of Spl mRNA and protein than do uninfected cells
(68). Genes which respond to increased Spl levels would
therefore be activated indirectly by T antigen.
What, then, does it mean for a mutant T to transactivate at
a reduced level? It could mean that there is less mutant T
antigen, but we think this unlikely, since most mutant T
antigens have nearly wild-type stability (86) and some T
antigens which transactivate well are quite unstable (e.g.,
dlA2433). A second but related possibility concerns posttranslational modifications. T antigen is phosphorylated at
multiple sites, glycosylated, ADP-ribosylated, and adenylylated. Many of these modifications occur on only a fraction
of T antigen molecules, leading to a diverse spectrum of T
antigen species. Perhaps only some are active in transacti-
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vation, and the relative abundance of different forms could
be affected by mutation. Third, if T transactivates through
multiple mechanisms, mutants with partial activity could
retain wild-type activity for one (or more) but be inactive in
another. Finally, mutants with reduced activity could continue to play the normal roles of wild-type T but interact less
effectively with the intracellular targets important for this
function.

A further question concerns the role of small t antigen in
transactivation. Small t has been reported to transactivate
the adenovirus E2 promoter but not the SV40 late promoter
(47). The fact that some of the mutants were completely
defective for transactivation yet produced a wild-type small
t suggests that small t was not playing a significant role in
transactivation of either of the promoters which we studied.
Loeken et al. (47) have suggested that small t can enhance
the ability of limiting amounts of large T to transactivate. A
related possibility is that small t could enhance the activity of
a transactivation-defective T antigen that is produced at
normal levels. Additional experiments will be required to
examine this possibility. It is worth pointing out that mutants
with lesions in the first exon, which showed reduced transactivation activity, encode mutant small t antigens in addition to mutant large Ts.
Are there correlations between transactivation by T antigen
and its other activities? Understanding how the transactivation activity of large T is related to its other properties is one
of the main purposes of these experiments and others
ongoing in our laboratory. The studies presented here suggest that some activities of T antigen are not important to
its transactivation function. Mutants defective in binding
of retinoblastoma susceptibility gene protein (K-1) (15), in
nuclear localization (SVcT [42]), in ATPase activity
(dlA2432), in p53 binding (dlA2433), and in the host rangeadenovirus helper function activity (dlA2459) transactivated
approximately as well as wild-type T antigen.
Previous work has demonstrated that immortalization of
primary mouse embryo fibroblasts requires most of large T
antigen (77) but that the first 127 amino acids of large T are
not needed. Transformation of C3H-10T1/2 mouse cells
requires only the N-terminal 120 to 130 amino acids (73), but
most studies have shown that transformation of many other
mouse and rat cell lines occurs with wild-type efficiency only
if most of the first 600 amino acids are present (59, 77).
Mutant dlA2433 is defective for immortalization of mouse
embryo fibroblasts (77, 80) yet transactivates both promoters
examined at wild-type levels. Mutant dlA2411 was completely defective for transactivation but immortalizes mouse
embryo fibroblasts (77) and transforms both mouse 1OT1/2
and rat REF-52 cell lines at wild-type efficiency (86a).
Together, these data suggest that the ability of mutant T
antigens to immortalize and transform is genetically distinct
from their transactivation activities. However, we cannot
eliminate the possibility that transformation, immortalization, or both require the transactivation of certain cellular
promoters; this ability could be lost in mutants which still
transactivate the SV40 late and RSV LTR promoters but
have lost the ability to immortalize or transform. In addition,
mutant T antigens could have a different spectrum of transactivation activities in cell lines of different types or derived
from different species.
Caution is clearly required in deciding whether T antigen's
ability to transactivate correlates with any of its other
properties. Some of these properties are easily measured
biochemical activities. Examples include ATP-binding, ATP
hydrolysis, and DNA binding. One can determine whether a
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mutation that affects these properties alters the Ki,m the
Vmax, or the binding constant for DNA. Other properties of
T, such as immortalization, transformation, and stimulation
of quiescent cells to undergo DNA replication, are considerably more complex and represent a phenotypic endpoint
which may be several steps downstream from a direct
biochemical action of T antigen. For example, if immortalization required the transactivation activity of T antigen, we
can imagine that immortalization might not be seen at all if
transactivation activity fell below a particular threshold, or,
conversely, that nearly wild-type activity for transactivation
could be required to obtain immortalization at levels exceeding 10% of wild-type levels.
In summary, our studies show that the sequences in the
N-terminal region of large T play a role in transactivation. In
the context of a full-length T antigen, mutations in additional
regions of the protein also affect transactivation. These other
regions may also have transactivating activity. However, we
favor the idea that the overall conformation of T is important
for transactivation and that this activity will be affected by
two sets of mutations. One set includes those that directly
modify the portion of the protein which mediates transactivation. The other are mutations which do not affect this
region but alter the overall conformation of T antigen and
thereby compromise its ability to perform its transactivation
function.
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